Total Payments
$29,005
2024 Payments
$7,715
Companies
5
Transactions
31
Medicare Patients
475
Medicare Billing
$86,385
Payment Breakdown by Category
Consulting$12,000 (41.4%)
Research$7,186 (24.8%)
Other$7,155 (24.7%)
Travel$1,917 (6.6%)
Food & Beverage$748.00 (2.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $12,000 | 3 | 41.4% |
| Unspecified | $7,186 | 1 | 24.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,155 | 6 | 24.7% |
| Travel and Lodging | $1,917 | 8 | 6.6% |
| Food and Beverage | $748.00 | 13 | 2.6% |
Payments by Type
General
$21,820
30 transactions
Research
$7,186
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $10,454 | 9 | $0 (2022) |
| SpringWorks Therapeutics, Inc. | $7,573 | 11 | $0 (2024) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $7,224 | 2 | $0 (2018) |
| Daiichi Sankyo Inc. | $3,612 | 8 | $0 (2023) |
| Deciphera Pharmaceuticals Inc. | $142.18 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,715 | 12 | SpringWorks Therapeutics, Inc. ($7,573) |
| 2023 | $117.57 | 1 | Daiichi Sankyo Inc. ($117.57) |
| 2022 | $13,948 | 16 | Boehringer Ingelheim Pharmaceuticals, Inc. ($10,454) |
| 2018 | $7,186 | 1 | NOVARTIS PHARMACEUTICALS CORPORATION ($7,186) |
| 2017 | $38.56 | 1 | Novartis Pharmaceuticals Corporation ($38.56) |
All Payment Transactions
31 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/12/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Travel and Lodging | Cash or cash equivalent | $62.70 | General |
| Category: DESMOID TUMORS | ||||||
| 09/12/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Travel and Lodging | Cash or cash equivalent | $35.00 | General |
| Category: DESMOID TUMORS | ||||||
| 09/12/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | Cash or cash equivalent | $22.15 | General |
| Category: DESMOID TUMORS | ||||||
| 08/29/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,047.50 | General |
| Category: DESMOID TUMORS | ||||||
| 08/20/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Travel and Lodging | In-kind items and services | $177.45 | General |
| Category: DESMOID TUMORS | ||||||
| 08/20/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $120.89 | General |
| Category: DESMOID TUMORS | ||||||
| 07/03/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,060.00 | General |
| Category: DESMOID TUMORS | ||||||
| 06/01/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $142.18 | General |
| Category: ONCOLOGY | ||||||
| 05/02/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $927.50 | General |
| Category: DESMOID TUMORS | ||||||
| 04/25/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $927.50 | General |
| Category: DESMOID TUMORS | ||||||
| 03/27/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $927.50 | General |
| Category: DESMOID TUMORS | ||||||
| 03/21/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $265.00 | General |
| Category: DESMOID TUMORS | ||||||
| 06/02/2023 | Daiichi Sankyo Inc. | Turalio (Drug) | Food and Beverage | In-kind items and services | $117.57 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2022 | Daiichi Sankyo Inc. | Turalio (Drug) | Consulting Fee | Cash or cash equivalent | $2,350.00 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2022 | Daiichi Sankyo Inc. | Turalio (Drug) | Consulting Fee | Cash or cash equivalent | $470.00 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2022 | Daiichi Sankyo Inc. | Turalio (Drug) | Travel and Lodging | In-kind items and services | $320.00 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2022 | Daiichi Sankyo Inc. | Turalio (Drug) | Travel and Lodging | In-kind items and services | $226.76 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2022 | Daiichi Sankyo Inc. | Turalio (Drug) | Food and Beverage | In-kind items and services | $68.66 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2022 | Daiichi Sankyo Inc. | Turalio (Drug) | Food and Beverage | In-kind items and services | $37.20 | General |
| Category: ONCOLOGY | ||||||
| 11/16/2022 | Daiichi Sankyo Inc. | Turalio (Drug) | Food and Beverage | In-kind items and services | $21.94 | General |
| Category: ONCOLOGY | ||||||
| 10/26/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $9,180.00 | General |
| 10/26/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $140.00 | General |
| 10/26/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 09/21/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $821.42 | General |
| 09/21/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $133.40 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $7,186 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 97 | 181 | $53,871 | $17,912 |
| 2022 | 3 | 105 | 230 | $65,636 | $22,546 |
| 2021 | 4 | 131 | 233 | $68,614 | $24,850 |
| 2020 | 5 | 142 | 253 | $67,304 | $21,077 |
Total Patients
475
Total Services
897
Medicare Billing
$86,385
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 33 | 67 | $21,385 | $6,983 | 32.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 48 | $10,890 | $4,378 | 40.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 20 | 39 | $12,419 | $4,137 | 33.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 13 | $5,858 | $1,765 | 30.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 11 | 14 | $3,318 | $648.87 | 19.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 29 | 75 | $22,553 | $7,888 | 35.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 36 | 78 | $23,467 | $7,597 | 32.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 27 | 64 | $14,039 | $5,072 | 36.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 13 | 13 | $5,578 | $1,989 | 35.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 38 | 76 | $22,238 | $8,066 | 36.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 27 | 57 | $16,678 | $5,965 | 35.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 26 | 60 | $12,839 | $4,846 | 37.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 27 | 27 | $11,261 | $4,227 | 37.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 13 | 13 | $5,598 | $1,746 | 31.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 27 | 68 | $14,551 | $5,529 | 38.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 39 | 70 | $20,482 | $5,460 | 26.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 30 | 65 | $19,019 | $5,433 | 28.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 18 | 18 | $7,508 | $2,821 | 37.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 17 | 18 | $2,706 | $1,006 | 37.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 11 | 14 | $3,038 | $828.14 | 27.3% |
About Dr. Anna Chalmers, MD
Dr. Anna Chalmers, MD is a Internal Medicine healthcare provider based in Salt Lake City, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/03/2010. The National Provider Identifier (NPI) number assigned to this provider is 1992025787.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anna Chalmers, MD has received a total of $29,005 in payments from pharmaceutical and medical device companies, with $7,715 received in 2024. These payments were reported across 31 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($12,000).
As a Medicare-enrolled provider, Chalmers has provided services to 475 Medicare beneficiaries, totaling 897 services with total Medicare billing of $86,385. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Salt Lake City, UT
- Active Since 06/03/2010
- Last Updated 11/11/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1992025787
Products in Payments
- OGSIVEO (Drug) $7,573
- TAFINLAR (Drug) $7,186
- Turalio (Drug) $3,612
- QINLOCK (Drug) $142.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Salt Lake City
Dr. Willard Dere, M.d, M.D
Internal Medicine — Payments: $5.4M
Internal Medicine $5.4M
Dr. Catherine Bakewell, M.d, M.D
Internal Medicine — Payments: $1.0M
Internal Medicine $1.0M
Dr. April Erwin, Md, MD
Internal Medicine — Payments: $381,757
Internal Medicine $381,757
Dr. Neeraj Agarwal, Md, MD
Internal Medicine — Payments: $344,790
Internal Medicine $344,790
George Rodgers, M.d, M.D
Internal Medicine — Payments: $229,629
Internal Medicine $229,629
James Chamberlain, Md, MD
Internal Medicine — Payments: $200,257
Internal Medicine $200,257